March 9th 2022
Pephexia receives Grant from the Danish Innovation Fund
Pephexia Therapeutics ApS have received a Grant of 4.7M DKK from the Danish Innovation Fund. This is the second grant following the successful execution of the first minor Innobooster project. Now in the second major Innobooster project it is the intention to mature Pephexia lead project for Cancer Cachexia towards Lead selection and characterization.
December 1st 2021
Pephexia receives funding from Vækstfonden
Pephexia has received a financing of 3M DKK/400.000 Euro from Vækstfonden (Danish Growth Fund). This funding enable advancement of our innovative peptide projects for the treatment of cachexia at full speed towards lead selection and characterization.
November 11th 2021
Pephexia hires Chief Business Officer (CBO)
Kamilla Rolsted joins a newly created position as Chief Business Officer (CBO) in Pephexia Therapeutics. Kamilla brings solid experience from positions in companies such as Zealand Pharma, Bionor Pharma, and Akari Therapeutics.
September 23rd 2021
Pephexia secures 10M DKK in funding via the Creation House program at BioInnovation Institute
Entering the Creation House program at BII is a major milestone in Pephexia’s efforts towards the development of effective and convenient treatments of cachexia and related diseases.
March 9th 2021
Pephexia selected to participate in NLSinvest2021
From hundreds of high-quality applications the Nordic Selection Committee has chosen Pephexia Therapeutics as one of the Rising Stars to join Nordic Life Science Invest. Pephexia Therapeutics is pleased to be able to pitch before 120+ global investors joining the NLSInvest & Nordic Life Science Days.
March 2nd 2021
Pephexia expands the organization
Pephexia strengthens its knowhow on peptide drug discovery by welcoming Søren Ljungberg Pedersen as new CTO & Head of Research and Professor Annette G. Beck-Sickinger as Scientific advisor.
January 1st 2021
Seasoned biotech profiles starts new company
A team of senior people in biotech join forces in a new biotech company set out to develop a novel medicine for unintended weight loss.
October 15th 2020
Pephexia receives Innobooster grant
Today Pephexia has received an Innobooster grant from Innovationsfonden, Denmark for funding of the lead peptide program for cachexia.
November 2nd 2020
Pephexia raised share capital
Pephexia has expanded the share capital by inclusion of active private investors for acceleration of the lead peptide program for cachexia.